1.
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab
for induction and maintenance therapy for ulcerative colitis. The New England journal
of medicine. 2005;353(23):2462-76.
2.
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab
(chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in
rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase
III trial. ATTRACT Study Group. Lancet (London, England). 1999;354(9194):1932-9.
3.
Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al. Major reduction
in spinal inflammation in patients with ankylosing spondylitis after treatment with
infliximab: results of a multicenter, randomized, double-blind, placebo-controlled
magnetic resonance imaging study. Arthritis and rheumatism. 2006;54(5):1646-52.
4.
Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab
improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Annals of the rheumatic diseases. 2005;64(8):1150-7.
5.
Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and
safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet
(London, England). 2001;357(9271):1842-7.
6.
Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and
importance of antibody responses to infliximab after maintenance or episodic treatment
in Crohn's disease. Clinical gastroenterology and hepatology : the official clinical
practice journal of the American Gastroenterological Association. 2004;2(7):542-53.
7.
Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies
in IBD. The American journal of gastroenterology. 2011;106(4):685-98.
8.
Fisher MD, Watson C, Fox KM, Chen YW, Gandra SR. Dosing patterns of three tumor necrosis
factor blockers among patients with rheumatoid arthritis in a large United States
managed care population. Current medical research and opinion. 2013;29(5):561-8.
9.
Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in
immune-mediated inflammatory diseases: a systematic review of the literature with
a meta-analysis. Annals of the rheumatic diseases. 2013;72(12):1947-55.
10.
Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes
and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
The American journal of gastroenterology. 2013;108(1):40-7; quiz 8.
11.
Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against
tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic
review and meta-analysis. JAMA Intern Med. 2013;173(15):1416-28.
12.
Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised,
double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics,
safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing
spondylitis: the PLANETAS study. Annals of the rheumatic diseases. 2013;72(10):1605-12.
13.
Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised,
double-blind, parallel-group study to demonstrate equivalence in efficacy and safety
of CT-P13 compared with innovator infliximab when coadministered with methotrexate
in patients with active rheumatoid arthritis: the PLANETRA study. Annals of the rheumatic
diseases. 2013;72(10):1613-20.
14.
Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity:
antibodies to infliximab in Remicade-treated patients with IBD similarly recognise
the biosimilar Remsima. Gut. 2015.
15.
Blom M, Kievit W, Kuper HH, Jansen TL, Visser H, den Broeder AA, et al. Frequency
and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily
clinical practice. Arthritis Care Res (Hoboken). 2010;62(9):1335-41.
16.
Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, et
al. Efficacy of treatment intensification with adalimumab, etanercept and infliximab
in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.
Semin Arthritis Rheum. 2013;43(2):144-51.
17.
Garces S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary
algorithm introducing immunogenicity assessment in the management of patients with
RA receiving tumour necrosis factor inhibitor therapies. Annals of the rheumatic diseases.
2014;73(6):1138-43.
18.
Dannepond C, Maruani A, Machet L, Ternant D, Paintaud G, Samimi M. Serum infliximab
concentrations in psoriatic patients treated with infliximab: a systematic review.
Acta Derm Venereol. 2015;95(4):401-6.
19.
Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized
monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients
treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis and rheumatism.
2006;54(12):3782-9.
20.
Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic
and clinical response to infliximab plus methotrexate in patients with rheumatoid
arthritis: results from the RISING study. Mod Rheumatol. 2009;19(5):478-87.
21.
Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development
of antiinfliximab antibodies and relationship to clinical response in patients with
rheumatoid arthritis. Arthritis and rheumatism. 2006;54(3):711-5.
22.
Warman A, Straathof JW, Derijks LJ. Therapeutic drug monitoring of infliximab in inflammatory
bowel disease patients in a teaching hospital setting: results of a prospective cohort
study. Eur J Gastroenterol Hepatol. 2015;27(3):242-8.
23.
Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association
between serum concentration of infliximab and efficacy in adult patients with ulcerative
colitis. Gastroenterology. 2014;147(6):1296-307.e5.
24.
Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K,
et al. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory
Bowel Disease. Gastroenterology. 2015.
25.
Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum
infliximab trough level and decrease of C-reactive protein level are associated with
durable sustained response to infliximab: a retrospective analysis of the ACCENT I
trial. Gut. 2014;63(11):1721-7.
26.
Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship
between infliximab concentrations, antibodies to infliximab and disease activity in
Crohn's disease. Gut. 2014.
27.
Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, et al. First trough level
of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative
colitis-results from a multicenter prospective randomized controlled trial and its
post hoc analysis. Journal of gastroenterology. 2016;51(3):241-51.
28.
Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of
anti-TNF therapy in treating inflammatory bowel disease. Expert opinion on biological
therapy. 2016;16(10):1277-90.
29.
Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy
in ulcerative colitis. Therapeutic advances in gastroenterology. 2016;9(4):548-59.
30.
Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF
Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
Inflammatory bowel diseases. 2016;22(8):1999-2015.
31.
Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and
biological disease-modifying antirheumatic drugs: 2016 update. Annals of the rheumatic
diseases. 2017;76(6):960-77.
32.
D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, et al. Increasing
Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does
Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With
Active Luminal Crohn's Disease. Gastroenterology. 2018;154(5):1343-51.e1.
33.
Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching
from originator infliximab to biosimilar CT-P13 compared with maintained treatment
with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority
trial. Lancet (London, England). 2017;389(10086):2304-16.
34.
Goll GL, Jorgensen KK, Sexton J, Olsen IC, Bolstad N, Haavardsholm EA, et al. Long-term
efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator
infliximab: open-label extension of the NOR-SWITCH trial. Journal of internal medicine.
2019.
35.
Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, et al.
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term
Mucosal Healing in Patients With Ulcerative Colitis. Clinical gastroenterology and
hepatology : the official clinical practice journal of the American Gastroenterological
Association. 2016;14(4):543-9.
36.
St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The
relationship of serum infliximab concentrations to clinical improvement in rheumatoid
arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled
trial. Arthritis and rheumatism. 2002;46(6):1451-9.
37.
Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF, et al. The efficacy
of shortening the dosing interval to once every six weeks in Crohn's patients losing
response to maintenance dose of infliximab. Alimentary pharmacology & therapeutics.
2011;33(3):349-57.
38.
Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, et al. Doubling
the infliximab dose versus halving the infusion intervals in Crohn's disease patients
with loss of response. Inflammatory bowel diseases. 2012;18(11):2026-33.